Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Obesity
Recruiting1 awardPhase 3
Hazel Crest, Illinois
This trial is to study the effect of semaglutide, a new medicine, on people with heart failure as well as their body weight. Participants will be randomly assigned to either take semaglutide or a placebo and will be monitored for 59 weeks. There will be 11 clinic visits and 1 phone call with the study doctor.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.